Hit Screening and Generation

  • Validated novel target(s) would have great value to be developed as novel therapies. For small molecule development, clients usually choose DNA-Encoding Library (DEL) platform to screen and generate hit/lead compounds, while for biologic development, the conventional way is to synthesis antigen, and immunize specific animal with the antigen to generate antibody. These generated small molecules or biologics could be further moved forward to drug R&D process, including lead optimization, candidate nomination, pre-clinical research, and finally for IND filing.

Hit Screening and Generation